What is the price target for CAI stock?
14 analysts have analysed CAI and the average price target is 37.43 USD. This implies a price increase of 109.13% is expected in the next year compared to the current price of 17.9.
CARIS LIFE SCIENCES INC (CAI) Forecast, Price Target & Analyst Ratings
NASDAQ:CAI • US1421521071
Current stock price
17.9 USD
-0.64 (-3.45%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CARIS LIFE SCIENCES INC (CAI).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.02
- Revenue Estimate
- 213.27M
Price Target Details & History
Consensus Price Target and Range
Mean target
$37.43
Upside
+ 109.13%
From current price of $17.90 to mean target of $37.43, Based on 14 analyst forecasts
Low
$26.26
Median
$38.25
High
$47.25
Price Target Revisions
1 Month
-3.14%
3 Months
-3.70%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for CAI. The average price target is 37.43 USD. This implies a price increase of 109.13% is expected in the next year compared to the current price of 17.9.
The average price target has been revised downward by 3.7% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.71%
CAI was analyzed by 14 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CAI.
In the previous month the buy percentage consensus was at a similar level.
CAI was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2026-02-27 | BTIG | Maintains | Buy -> Buy |
| 2026-02-27 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-27 | Baird | Maintains | Outperform -> Outperform |
| 2026-02-17 | Baird | Initiate | Outperform |
| 2025-12-22 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-12-02 | Canaccord Genuity | Initiate | Hold |
| 2025-08-13 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-13 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-08-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-15 | Evercore ISI Group | Initiate | Outperform |
| 2025-07-14 | TD Cowen | Initiate | Buy |
| 2025-07-14 | Guggenheim | Initiate | Buy |
| 2025-07-14 | Wolfe Research | Initiate | Outperform |
| 2025-07-14 | JP Morgan | Initiate | Overweight |
| 2025-07-14 | Citigroup | Initiate | Buy |
| 2021-06-30 | Keefe, Bruyette & Woods | Downgrade | Outperform -> Market Perform |
| 2021-06-21 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021-06-18 | B. Riley Securities | Downgrade | Buy -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.02
- Revenue Estimate
- 213.27M
- Revenue Q2Q
- 76.38%
- EPS Q2Q
- N/A
- Number of Analysts
- 11
Next Earnings Revisions
Revenue (1 Month)
2.23%
Revenue (3 Months)
16.74%
EPS (1 Month)
4,308.00%
EPS (3 Months)
168.98%
Next Earnings Summary
The next earnings revenue estimate has been revised upward by 16.74% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A 10.80% | 306.128M -24.35% | 412.26M 34.67% | 763.09M 85.10% | 1.009B 32.23% | 1.237B 22.60% | 1.443B 16.65% | 1.633B 13.17% | 1.842B 12.80% | 1.922B 4.34% | |
| EBITDA YoY % growth | N/A | -270.55M | -208.209M 23.04% | 72.04M 134.60% | 166.34M 130.90% | 271.2M 63.04% | 354.6M 30.75% | 485.25M 36.84% | 555.55M 14.49% | 656.8M 18.23% | |
| EBIT YoY % growth | N/A | -319.551M | -257.122M 19.54% | -1.001M 99.61% | 105.78M 10,666.04% | 221.51M 109.41% | 325.99M 47.17% | 361.88M 11.01% | 464.63M 28.39% | 474.2M 2.06% | |
| Operating Margin | N/A | -104.38% | -62.37% | -0.13% | 10.48% | 17.91% | 22.59% | 22.16% | 25.22% | 24.67% | |
| EPS YoY % growth | N/A 13.34% | N/A -18.46% | N/A -3.52% | -2.01 -128.65% | 0.19 109.60% | 0.39 100.91% | 0.65 68.46% | 0.73 11.51% | 0.86 18.06% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.02 | 0.05 100.64% | 0.06 -25.22% | 0.11 -60.92% | 0.07 435.05% | 0.15 197.03% | 0.19 212.96% | 0.21 93.85% |
| Revenue Q2Q % growth | 213.27M 76.38% | 250.61M 38.15% | 256.09M 18.10% | 283.19M -3.31% | 268.71M 26.00% | 312.39M 24.65% | 315.63M 23.25% | 335.93M 18.62% |
| EBITDA Q2Q % growth | 23.63M 146.42% | 42.252M 1,031.69% | 55.134M 8.18% | 74.908M 104.19% | 55.702M 135.73% | 79.891M 89.08% | 92.87M 68.44% | 99.081M 32.27% |
| EBIT Q2Q % growth | -897.769K 98.45% | 17.78M 198.84% | 30.55M -6.41% | 42.258M 84.52% | 29.745M 3,413.21% | 55.348M 211.29% | 67.771M 121.84% | 73.983M 75.07% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
19.27%
EPS Next 5 Year
-19.81%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
5.04%
Revenue Next 5 Year
17.18%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
45.10%
EBIT Next 5 Year
31.20%
CARIS LIFE SCIENCES INC / CAI Forecast FAQ
Can you provide the consensus estimates for CARIS LIFE SCIENCES INC next earnings?
The consensus EPS estimate for the next earnings of CARIS LIFE SCIENCES INC (CAI) is -0.02 USD and the consensus revenue estimate is 213.27M USD.
What is the consensus rating for CAI stock?
The consensus rating for CARIS LIFE SCIENCES INC (CAI) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.